Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06930755 · ClinicalTrials.gov registry record · Phase 1
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
A Phase 1 study of Ovarian Cancer, sponsored by Nerviano Medical Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 5
- Study locations
NCT06930755 is a Phase 1 study of Ovarian Cancer that is actively recruiting participants, run by Nerviano Medical Sciences. The registered enrollment target is 24 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT06930755, a Phase 1 study of Ovarian Cancer, is actively recruiting participants, sponsored by Nerviano Medical Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with topotecan.
Conditions Studied
Interventions
- DRUG NMS-03305293
- DRUG Topotecan
Study Locations (5)
Illinois
- OSF Saint Francis Medical Center - Peoria
Missouri
- Washington University School of Medicine in St. Louis - St Louis
Pennsylvania
- Penn Medicine - Perelman Center for Advanced Medicine - Philadelphia
Tennessee
- Tennessee Oncology - Nashville
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-01-31 |
| Est. Completion | 2027-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06930755
The ClinicalTrials.gov registry entry for NCT06930755 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Nerviano Medical Sciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which NMS-03305293 is the first listed.
NCT06930755 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Missouri, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06930755 about?
NCT06930755 is a clinical study titled "Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer". This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to eva...
What is the current status of trial NCT06930755?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-01-31. Estimated completion is 2027-09-26.
What conditions does trial NCT06930755 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT06930755?
The interventions under investigation include: NMS-03305293 (DRUG), Topotecan (DRUG).
Who is sponsoring clinical trial NCT06930755?
This trial is sponsored by Nerviano Medical Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06930755 being conducted?
This trial has 5 study locations across Illinois, Missouri, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.